1 / 27

Endovascular ThoracoAbdominal Aneurysm Repair

Endovascular ThoracoAbdominal Aneurysm Repair. The French Prospective Multicenter Trial 2 Year Follow Up. Disclosure Statement None. STRATO The French Prospective Multicenter Study 2-Year Follow-up.

lysandra-jarvis
Télécharger la présentation

Endovascular ThoracoAbdominal Aneurysm Repair

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Endovascular ThoracoAbdominal Aneurysm Repair The French Prospective Multicenter Trial 2 Year Follow Up

  2. Disclosure Statement None

  3. STRATO The French Prospective Multicenter Study 2-Year Follow-up Enrollment: April 2010 - February 2011 – 10 centers 23 pts (4 female, 19 male), Age76y ± 11y (59-93y) CT imaging at 1-3-6-12-24 months Corelab (CERC – France) C Vaislic, JN Fabiani, S Chocron, JM Alsac, Y Glock, H Rousseau, P Leprince, J Robin, T Unterseeh, JP Villemot, V Costache, M Sapoval,

  4. STRATO The French Prospective Multicenter Study 2-Year Follow-up Non expert centers No learning curve First generation MFM C Vaislic, JN Fabiani, S Chocron, JM Alsac, Y Glock, H Rousseau, P Leprince, J Robin, T Unterseeh, JP Villemot, V Costache, M Sapoval,

  5. Clinical Event Commitee

  6. STRATO The French Prospective Multicenter Study 2-Year Follow-up Primary efficacy endpoint : Aneurysm exclusion Collateral patency Primary safety endpoint : All cause Mortality

  7. STRATO The French Prospective Multicenter Study 2-Year Follow-up Secondaryendpoints: Type I or III endoleaks Secondary open or endovascularprocedure Spinal cord ischemia Stent migration or loss of stent integrity aneurysm rupture major adverse events Change of size Maximum Diameter Volume (thrombus and flow)

  8. STRATO The French Prospective Multicenter Study 2-Year Follow-up • Age >=80 • ASA >=3 • Hx of Aortic Surgery • CAD • Cardiac Renal or Respiratory Insufficiency • Hostile Abdomen / Thorax

  9. Pt History

  10. Previous Aortic Intervention

  11. Aneurysm Description • 10 Crawford Type II (43.5 %) • 13 Crawford Type III (56.5 %) • Mean Diameter: 65 mm (46 –85mm) • Length: 162.5 mm (36-408mm)

  12. Procedural Data

  13. Mortality • Explantation • Lost to follow up • refuses CT scan ( chemotherapy CA)

  14. Major Adverse Events

  15. No Spinal cordischemia • No respiratory, renal or peripheral complications

  16. No Aneurysm Rupture, No Migration, No Stent Fracture

  17. Visceral Branch Patency At 24 months in 17 pts : 2 occluded branches / 57 covered branches (96,5 %)

  18. Endoleaks • Endoleak was reported in 3 pts (17%) • 1 corrected by stent-graft • 2 corrected with secondary intervention (MFM)

  19. Clinical Success

  20. Change in size

  21. Change in size

  22. Thrombus change vs residual flow(all patients [n=17]) All residual flow are less then 20% except 1 with 45 % (endoleak type I)

  23. Evolution of the Max Diameter (all patients [n=17])

  24. Evolution of the Max Diameter (all patients [n=17])

  25. Evolution of the Max Diameter (Patients without endoleak or inflammation [n=13])

  26. STRATO Study: 2-years Results

  27. Conclusion • All aneurysms thrombosed with a residual flow =< 20% (except 1 with endoleak type I non treated) • At 2 years 15/17 (88%) have stable aneurysm diameter

More Related